Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle

The gamma-herpesvirus Epstein-Barr virus (EBV) persists for life in infected individuals despite the presence of a strong immune response. During the lytic cycle of EBV many viral proteins are expressed, potentially allowing virally infected cells to be recognized and eliminated by CD8+ T cells. We have recently identified an immune evasion protein encoded by EBV, BNLF2a, which is expressed in early phase lytic replication and inhibits peptide- and ATP-binding functions of the transporter associated with antigen processing. Ectopic expression of BNLF2a causes decreased surface MHC class I expression and inhibits the presentation of indicator antigens to CD8+ T cells. Here we sought to examine the influence of BNLF2a when expressed naturally during EBV lytic replication. We generated a BNLF2a-deleted recombinant EBV (ΔBNLF2a) and compared the ability of ΔBNLF2a and wild-type EBV-transformed B cell lines to be recognized by CD8+ T cell clones specific for EBV-encoded immediate early, early and late lytic antigens. Epitopes derived from immediate early and early expressed proteins were better recognized when presented by ΔBNLF2a transformed cells compared to wild-type virus transformants. However, recognition of late antigens by CD8+ T cells remained equally poor when presented by both wild-type and ΔBNLF2a cell targets. Analysis of BNLF2a and target protein expression kinetics showed that although BNLF2a is expressed during early phase replication, it is expressed at a time when there is an upregulation of immediate early proteins and initiation of early protein synthesis. Interestingly, BNLF2a protein expression was found to be lost by late lytic cycle yet ΔBNLF2a-transformed cells in late stage replication downregulated surface MHC class I to a similar extent as wild-type EBV-transformed cells. These data show that BNLF2a-mediated expression is stage-specific, affecting presentation of immediate early and early proteins, and that other evasion mechanisms operate later in the lytic cycle.

[1]  M. Ressing,et al.  The Epstein-Barr Virus G-Protein-Coupled Receptor Contributes to Immune Evasion by Targeting MHC Class I Molecules for Degradation , 2009, PLoS pathogens.

[2]  P. Deegen,et al.  The Immune Evasion Paradox: Immunoevasins of Murine Cytomegalovirus Enhance Priming of CD8 T Cells by Preventing Negative Feedback Regulation , 2008, Journal of Virology.

[3]  M. Ressing,et al.  The DNase of Gammaherpesviruses Impairs Recognition by Virus-Specific CD8+ T Cells through an Additional Host Shutoff Function , 2007, Journal of Virology.

[4]  M. Ressing,et al.  A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates , 2007, The Journal of experimental medicine.

[5]  M. Munks,et al.  Viral Interference with Antigen Presentation Does Not Alter Acute or Chronic CD8 T Cell Immunodominance in Murine Cytomegalovirus Infection1 , 2007, The Journal of Immunology.

[6]  M. Ressing,et al.  Host shutoff during productive Epstein–Barr virus infection is mediated by BGLF5 and may contribute to immune evasion , 2007, Proceedings of the National Academy of Sciences.

[7]  J. Yewdell,et al.  The DRiP hypothesis decennial: support, controversy, refinement and extension. , 2006, Trends in immunology.

[8]  E. Kieff,et al.  Virus and Cell RNAs Expressed during Epstein-Barr Virus Replication , 2006, Journal of Virology.

[9]  J. Neefjes,et al.  MHC class I alleles and their exploration of the antigen‐processing machinery , 2005, Immunological reviews.

[10]  H. Ploegh,et al.  Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond , 2005, Immunological reviews.

[11]  M. Ressing,et al.  Impaired Transporter Associated with Antigen Processing-Dependent Peptide Transport during Productive EBV Infection1 , 2005, The Journal of Immunology.

[12]  A. Rickinson,et al.  CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells , 2005, The Journal of experimental medicine.

[13]  U. Koszinowski,et al.  Murine Cytomegalovirus Interference with Antigen Presentation Has Little Effect on the Size or the Effector Memory Phenotype of the CD8 T Cell Response1 , 2004, The Journal of Immunology.

[14]  K. Früh,et al.  Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. , 2004, Immunity.

[15]  G. Griffiths,et al.  The role of the secretory immunological synapse in killing by CD8+ CTL. , 2003, Seminars in immunology.

[16]  E. Wiertz,et al.  Viral immune evasion: a masterpiece of evolution , 2002, Immunogenetics.

[17]  M. Rowe,et al.  The Lytic Cycle of Epstein-Barr Virus Is Associated with Decreased Expression of Cell Surface Major Histocompatibility Complex Class I and Class II Molecules , 2002, Journal of Virology.

[18]  U. Koszinowski,et al.  K3-mediated evasion of CD8+ T cells aids amplification of a latent γ-herpesvirus , 2002, Nature Immunology.

[19]  A. Rickinson,et al.  Epitope-specific Evolution of Human CD8+ T Cell Responses from Primary to Persistent Phases of Epstein-Barr Virus Infection , 2002, The Journal of experimental medicine.

[20]  P. Rivailler,et al.  Complete Nucleotide Sequence of the Rhesus Lymphocryptovirus: Genetic Validation for an Epstein-Barr Virus Animal Model , 2002, Journal of Virology.

[21]  U. Koszinowski,et al.  K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus. , 2002, Nature immunology.

[22]  A. Rickinson,et al.  Processing of a Multiple Membrane Spanning Epstein-Barr Virus Protein for Cd8+T Cell Recognition Reveals a Proteasome-Dependent, Transporter Associated with Antigen Processing–Independent Pathway , 2001, The Journal of experimental medicine.

[23]  M. Bonneville,et al.  A global appraisal of immunodominant CD8 T cell responses to Epstein‐Barr virus and cytomegalovirus by bulk screening , 2000, European journal of immunology.

[24]  W. Hammerschmidt,et al.  The Epstein–Barr virus lytic program is controlled by the co‐operative functions of two transactivators , 2000, The EMBO journal.

[25]  W. Hammerschmidt,et al.  Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Nicholls,et al.  Epstein‐Barr virus expression within keratinizing nasopharyngeal carcinoma , 1998, Journal of medical virology.

[27]  Jaap M Middeldorp,et al.  A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. , 1997, Virology.

[28]  A. Kumar,et al.  Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response , 1997, The Journal of experimental medicine.

[29]  M. Bonneville,et al.  T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis , 1996, The Journal of experimental medicine.

[30]  H. Ploegh,et al.  Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Biegalke Regulation of human cytomegalovirus US3 gene transcription by a cis-repressive sequence , 1995, Journal of virology.

[32]  S. Modrow,et al.  Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus , 1995, Journal of virology.

[33]  E. van Heerde,et al.  Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins , 1993, Journal of virology.

[34]  D. Tenney,et al.  Human cytomegalovirus UL36-38 and US3 immediate-early genes: temporally regulated expression of nuclear, cytoplasmic, and polysome-associated transcripts during infection , 1991, Journal of virology.

[35]  G. Packham,et al.  Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia , 1991, Journal of virology.

[36]  U. Nater,et al.  Epstein-Barr virus. , 1991, The Journal of family practice.

[37]  T. Jones,et al.  Fine mapping of transcripts expressed from the US6 gene family of human cytomegalovirus strain AD169 , 1991, Journal of virology.

[38]  M. Buisson,et al.  The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R , 1989, Journal of virology.

[39]  E. Kieff,et al.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. , 1989, The New England journal of medicine.

[40]  K. Takada,et al.  Synchronous and sequential activation of latently infected Epstein-Barr virus genomes , 1989, Journal of virology.

[41]  J. Poduslo,et al.  Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen. , 1984, Virology.